A Turning Point for Clinical Mass Spec? - Summary - MDSpire

A Turning Point for Clinical Mass Spec?

As Roche Diagnostics secures a first-of-its-kind CLIA designation, Allyson Kozak considers what it means for the future of clinical mass spectrometry

  • By

  • James Strachan

  • July 3, 2026

  • 6 min

Share

Original Source(s)

A Turning Point for Clinical Mass Spec?

  • by James Strachan

  • July 3, 2026

Related Content

Editorial: Mechanisms of endocrine cell proliferation in the embryonic, neonatal and adult pancreas

Steroid-related mechanisms in ocular health and disease: therapeutic effects, adverse events, and stress-related modulators. A narrative literature overview

The impact of the traditional Chinese spring festival on glycemic control in a hospital population: a lag time-window analysis of 300,046 HbA1c tests